Speaker List - MarketsandMarkets Digital Event on Orphan Drugs and Rare Diseases( Time Zone - EASTERN STANDARD TIME (EST)

MarketsandMarkets Digital Event on Orphan Drugs and Rare Diseases( Time Zone - EASTERN STANDARD TIME (EST)

9 - 10 July 2020
CONFERENCE SPEAKERS
Speakers
Scott Schliebner
Scott Schliebner
Senior Vice President, Center for Rare Diseases ,
PRA Health Sciences



Karen Frascello
Karen Frascello
Director, Global Medical Affairs, Early Access ,
Alnylam Pharmaceuticals



Dan Donovan
Dan Donovan
Founder & CEO ,
rareLife solutions



Dr. Michal Konstacky MD, PhD, MBA
Dr. Michal Konstacky MD, PhD, MBA
Global Medical Lead SHP 647 ,
Shire Pharmaceuticals



Stavros Ntogiakos
Stavros Ntogiakos
Regional Head of Rare Ocular Disease,
Novartis



Pedro Lendinez Ortega
Pedro Lendinez Ortega
Key Account Manager,
en Recordati Rare Diseases



Stephen Groft
Stephen Groft
Senior Advisor to the Director NCATS, ,
NIH


Steve is a Senior Advisor to the Director, NCATS at NIH.  He helped establish the Office of Orphan Products Development at FDA in 1982, the rare diseases initiative at NIH in 1989, Director of the Office of Rare Diseases Research from 1993-2014. His major focus has been on stimulating research with rare diseases and orphan products and developing information for patients, families, health care providers, research investigators, the biopharmaceutical industry, and the public. The emphasis included information about rare diseases, active and completed clinical trials, ongoing research, and patient advocacy groups.  He has co-authored numerous journal articles, book chapters on Rare Diseases Epidemiology. 


John Lagus
John Lagus
Managing Director of Business Development,
Tanner Pharma Group



Evelina Paberze
Evelina Paberze
Chief Operating Officer,
HRA Pharma Rare Diseases



Gregory R Stewart
Gregory R Stewart
PhD- Senior Vice President, Vector Delivery and Optimization,
Axovant Sciences



Monica Vinhas de Souza, MD, PhD
Monica Vinhas de Souza, MD, PhD
Executive Member of the research and ethics committee,
Hospital de ClĂ­nicas de Porto Alegre (HCPA)


 Areas of expertise: Internal Medicine. Rare disease. Clinical Epidemiology. HTA. Rational Use of Medicines. Pharmacovigilance. She is a member of the ISPOR Rare Diseases special interest group. Dr. Vinhas de Souza is a MD, with Master of Science in Clinical Epidemiology at NIHES-Erasmus University (NL) and PhD in Medicine-area: HTA and rare diseases- UFRGS (BR). She acts as Consultant to the Brazilian National Commission for Incorporation of Health

Technologies (CONITEC): medicines, rare diseases and HTA.

She is a Researcher at the Clinical Genetics HTA Group and Collaborates with the Exceptional Medicines Commission (COMEX), both at the Hospital de Clínicas de Porto Alegre/HCPA/Brazil.

Also, at HCPA, she works at the 'Drugs and Therapeutics Committee' and at the 'HCPA Research Committee and Ethics in Research Committee'.

Formerly she was a Scientific Administrator at European Medicines Agency/EMA in London, UK (risk management and safety: areas oncology, haematology and autoimmune diseases).


Neil Watson
Neil Watson
Director, Global Business Development ,
Clinigen Group



Jonathan Morton PhD
Jonathan Morton PhD
Agency lead,
Comradis Limited



Christine Von Raesfeld
Christine Von Raesfeld
Founder/CEO,
People with Empathy